Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-intensity unrelated donor allogeneic hematopoietic progenitor transplantation with post-transplant sirolimus-based GVHD prophylaxis
2007-006416-32Phase 2Completed
- Sponsor
- Fundación GEL
- Start
- Feb 2008
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sirolimus and tacrolimus in hematopoietic malignancies and graft-versus-host disease (GVHD) (2 arms), sponsored by Fundación GEL. Primary endpoints: Incidence and characteristics of acute and chronic graft-versus-host disease at 1 year and Comparison with historical cyclosporine A plus mycophenolate mofetil series. Started Feb 2008; status: completed.
02
Drugs
sirolimustacrolimus
03
Conditions
hematopoietic malignanciesgraft-versus-host disease (GVHD)
Beyond the preview
Go deeper on 2007-006416-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006416-32.